Regulation of heparanase expression in coronary artery disease in diabetic, hyperlipidemic swine.
about
Involvement of heparanase in atherosclerosis and other vessel wall pathologiesHeparanase regulates thrombosis in vascular injury and stent-induced flow disturbanceSoluble heparan sulfate fragments generated by heparanase trigger the release of pro-inflammatory cytokines through TLR-4.Macrophage activation by heparanase is mediated by TLR-2 and TLR-4 and associates with plaque progression.Heparanase induced by advanced glycation end products (AGEs) promotes macrophage migration involving RAGE and PI3K/AKT pathwayHeparan Sulfate Regrowth Profiles Under Laminar Shear Flow Following Enzymatic Degradation.Loss of syndecan-1 induces a pro-inflammatory phenotype in endothelial cells with a dysregulated response to atheroprotective flow.Oxidation and modification of extracellular matrix and its role in disease.How do we prevent the vulnerable atherosclerotic plaque from rupturing? Insights from in vivo assessments of plaque, vascular remodeling, and local endothelial shear stress.Overcoming disease-induced growth factor resistance in therapeutic angiogenesis using recombinant co-receptors delivered by a liposomal system.Reactive oxygen species mediate high glucose-induced heparanase-1 production and heparan sulphate proteoglycan degradation in human and rat endothelial cells: a potential role in the pathogenesis of atherosclerosis.Syndesome Therapeutics for Enhancing Diabetic Wound HealingGlypican-1 nanoliposomes for potentiating growth factor activity in therapeutic angiogenesisA novel system for studying mechanical strain waveform-dependent responses in vascular smooth muscle cells.Heparanase Inhibition Reduces Glucose Levels, Blood Pressure, and Oxidative Stress in Apolipoprotein E Knockout Mice.Glycosaminoglycans contribute to extracellular matrix fiber recruitment and arterial wall mechanics.Advanced glycation end-products induce heparanase expression in endothelial cells by the receptor for advanced glycation end products and through activation of the FOXO4 transcription factor.Algal Polysaccharides as Therapeutic Agents for Atherosclerosis
P2860
Q27025052-A702435C-9894-4CC2-B8C9-6F57969501B8Q28264895-4A311E72-6379-4911-86CB-365367B50389Q35312128-AC243F32-1873-4837-82B7-60D19488628FQ36542354-A337102A-2445-42C2-96A2-D681C101C64DQ36797594-7B938811-2B2E-45D7-898C-79BAA93ECC70Q36947609-ED35F984-00DB-439E-9646-AFF5B26C7CFAQ37683359-DE161C58-C61B-4B4F-ACC5-94EC2449D52AQ38209427-79390DA5-13FD-4D66-B9E1-80F50CDE3112Q38261883-11873C47-4C60-46B8-85C8-B9A44B0AC490Q38311837-E0E2E7AD-F9EC-4DDA-A946-2D5A7E42639FQ39572643-CF2A8F95-9CFD-4E03-BCAD-4FD61EF7DD58Q41421987-AE1FAFF0-56CA-44E8-BDB1-9C9DA3AE2070Q41728328-62FC85B3-51E8-4529-A5AF-192A3D303213Q41890576-D3B1A6C5-989E-4F54-B19E-348FF2BCD6EEQ46068605-8DD3AB4B-7F69-40FD-BEA5-6B469D3E872DQ51216476-A6C80E78-2526-4953-8156-31606AD992DAQ54599158-D73D6AF6-B240-483E-BB26-A54EB5187026Q58707225-0E107B61-C419-4F9D-86CD-7D04C81449F0
P2860
Regulation of heparanase expression in coronary artery disease in diabetic, hyperlipidemic swine.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Regulation of heparanase expre ...... iabetic, hyperlipidemic swine.
@en
Regulation of heparanase expre ...... iabetic, hyperlipidemic swine.
@nl
type
label
Regulation of heparanase expre ...... iabetic, hyperlipidemic swine.
@en
Regulation of heparanase expre ...... iabetic, hyperlipidemic swine.
@nl
prefLabel
Regulation of heparanase expre ...... iabetic, hyperlipidemic swine.
@en
Regulation of heparanase expre ...... iabetic, hyperlipidemic swine.
@nl
P2093
P2860
P1433
P1476
Regulation of heparanase expre ...... iabetic, hyperlipidemic swine.
@en
P2093
Aaron B Baker
Ahmet U Coskun
Benjamin V Stone
Campbell Rogers
Charles L Feldman
Elazer R Edelman
Konstantinos C Koskinas
Michael Jonas
Peter H Stone
Roy Beigel
P2860
P304
P356
10.1016/J.ATHEROSCLEROSIS.2010.09.003
P577
2010-09-18T00:00:00Z